Form 4: Voyager Therapeutics CSO Sells Shares for Tax Obligations

Voyager Therapeutics' Chief Scientific Officer, Todd Alfred Carter, sold 3,525 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Todd Alfred Carter, Chief Scientific Officer of Voyager Therapeutics, Inc. (VYGR), reported a transaction involving the sale of common stock.
• The transaction occurred on February 10, 2026, and involved the disposition of 3,525 shares of common stock.
• The shares were sold at a weighted average price of $3.85 per share, with individual sales ranging from $3.71 to $3.91.
• The sale was not a discretionary trade but was executed pursuant to a durable automatic sales instruction letter to satisfy tax withholding obligations from restricted stock units (RSUs) that vested on February 9, 2026.
• Following this transaction, Todd Alfred Carter beneficially owns 153,193 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this transaction as neutral. It is a routine, non-discretionary sale by an insider to cover tax obligations associated with RSU vesting, which is a common event and does not reflect a change in the executive's outlook on the company.

Positives

• The vesting of restricted stock units (RSUs) on February 9, 2026, indicates compensation for the Chief Scientific Officer, which can be a positive for executive retention and motivation.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if for tax purposes, decreases their direct equity stake in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales do not represent a discretionary trade by the reporting person, but rather a sell-to-cover election to satisfy tax withholding obligations in connection with RSU vesting.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a common and routine occurrence for executives receiving equity compensation, particularly restricted stock units, across various industries. These sales are typically administrative and not indicative of an executive's sentiment about the company's future prospects, unlike discretionary open-market sales.

Comparison to Industry Standards

• This type of transaction is standard practice for executives in publicly traded companies globally who receive equity compensation. It aligns with common corporate governance practices for managing tax liabilities arising from RSU vesting.
• Comparable transactions are frequently observed across the biotechnology and pharmaceutical sectors, where equity-based compensation is a significant component of executive remuneration.

Stakeholder Impact

• Shareholders: The impact is minimal as it is a routine, non-discretionary sale for tax purposes and does not signal a change in company fundamentals or executive confidence.
• Employees: No direct impact on employees is indicated by this filing.
• Management: The Chief Scientific Officer's equity compensation has vested, and a portion was sold to cover taxes, which is a standard part of executive compensation.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Form 4, Insider Transaction, Stock Sale, Chief Scientific Officer, RSU Vesting, Tax Withholding, Equity Compensation